ICB are molecules that restore the immune system’s ability to recognize and eliminate tumor cells such as PD1/PDL1 (program cell-death protein one and its ligand) or CTLA4 (cytotoxic T-lymphocyte associated protein 4) inhibitors have revolutionized the treatment of some adult cancers (Nishino et al., 2017). This evidence concerns the gene CTLA4 and neoplasm.